RA
PHAT icon

RiverPark Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

RiverPark Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,807
Closed -$46.6K – 165
2025
Q4 		$46.6K Buy
+2,807
New +$40.1K 0.01% 143

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

RiverPark Advisors's PHAT Position: Q1 2026 in Review

RiverPark Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 2,807 shares — an estimated $46.6K sold.

RiverPark Advisors first reported a position in PHAT in Q4 2025 and held it in 1 quarter. The position peaked at $46.6K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • RiverPark Advisors reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • RiverPark Advisors sold 2,807 Phathom Pharmaceuticals shares in Q1 2026, an estimated $46.6K.
  • RiverPark Advisors first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • RiverPark Advisors's Phathom Pharmaceuticals position peaked at $46.6K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on RiverPark Advisors's 13F filing for Q1 2026, filed 14 May 2026.